Disclosure: This site documents the founder’s personal research and self-experimentation. Nothing here is medical advice. Consult a physician before using any research compound.
The most common beginner mistake in peptide use isn’t a wrong compound. It isn’t a bad vendor. It isn’t even a dosing error, though those happen too.
It’s doing too much at once.
I’ve watched this pattern repeat enough times — in forums, in DMs, in my own early thinking about this — that I’m convinced it’s structural, not individual. The first protocol most people design involves three to five compounds, a complex injection schedule, and a theory about synergy that hasn’t been tested in any model. The reasoning sounds coherent. When something goes wrong, or right, they have no idea which variable caused it.
This is a protocol guide for people who haven’t run a peptide before. It argues for a single-compound starting point, explains how to read the evidence hierarchy before you act on it, and lays out what a responsible first cycle actually looks like — including what you’ll know at the end of it that you didn’t know at the start.
One note on sourcing: the community data scraped for this piece was thin. Where I cite dosing ranges or cycle structures, I’m drawing from the published literature and from patterns I’ve observed across forum discussion over time — not from a synthesized consensus I can point to. Where human data doesn’t exist, I’ll say so directly.
What You’re Actually Deciding
Before compound selection, before dosing, before sourcing — there’s a prior question most beginner guides skip.
What outcome are you trying to produce, and how would you know if you produced it?
This matters because peptides don’t work uniformly. BPC-157 is not interchangeable with a growth hormone secretagogue, and neither is interchangeable with TB-500. Each operates through a different mechanism, targets different tissue, and has a different evidence base. A protocol built around “general optimization” is not a protocol. It’s a shopping list.
The cleaner starting frame: identify one specific, measurable outcome. Injury recovery. Sleep quality tracked with hardware. Fasting IGF-1 tested before and after. Body composition measured with DEXA. Something you can evaluate. Something that gives you data on whether the compound did what you hypothesized.
This isn’t methodological perfectionism. It’s the only way a first cycle teaches you anything.
The Evidence Landscape Before You Start
Peptides are not a uniform category of compound, and the evidence behind them is not uniform either. Before selecting anything, you need to understand what kind of evidence exists — and what it cannot tell you.
The Human Data Problem
For most research peptides, human RCT data is either absent, limited to specific clinical populations, or decades old at doses that don’t map to current use. This is not a reason to dismiss the compounds. It is a reason to be precise about what you’re claiming when you use them.
BPC-157 has substantial rodent data — a 2012 review by Sikiric et al. in the Journal of Physiology Paris synthesized findings across multiple rat models showing accelerated tendon, muscle, and bone repair. Human trial data is sparse. One phase II trial was initiated but results remain unpublished. You can decide what that means for your risk calculus. You cannot cite it as human evidence.
Ipamorelin has more human exposure data, largely from surgical recovery research. A 2014 study (Nass et al., JCEM) examined related GHRPs in human subjects and found predictable GH pulse amplification. The selectivity advantage frequently cited for ipamorelin — less cortisol and prolactin co-stimulation than GHRP-6 — is established in animal models. The head-to-head human data is limited.
Knowing which rung of the evidence ladder a compound sits on is part of running a responsible protocol. If the vocabulary here is unfamiliar, read the plain-English primer on what peptides are before continuing.
The Legal Landscape
Peptides sold for research use exist in a specific legal space that shifted in 2024. Understanding that space is not optional. What can be compounded, what cannot, and what the FDA’s current enforcement posture looks like is covered in detail in our peptide legality breakdown. Read it before you source anything.
Compound Selection for a First Beginner Peptide Protocol
The principle: one compound, one variable, one outcome. Three compounds are worth considering for a first run.
| Compound | Best Use Case | Evidence Level | Key Biomarker |
|---|---|---|---|
| BPC-157 | Connective tissue / gut repair | Rodent: strong · Human: sparse | Pain scale (VAS) + function |
| Ipamorelin | GH pulse optimization | Rodent: strong · Human: indirect | Fasting IGF-1 |
| TB-500 | Systemic recovery | Rodent: moderate · Human: limited | Recovery rate + inflammation markers |
BPC-157 for Connective Tissue or Gut Repair
Mechanism: BPC-157 is a pentadecapeptide derived from a protein found in human gastric juice. In rodent models, it appears to upregulate growth factor receptors and promote angiogenesis at injury sites. The Sikiric lab has published extensively across tendon, muscle, ligament, and gut tissue models (Current Pharmaceutical Design, Journal of Physiology Paris, 2010–2018).
Evidence level: Essentially absent in peer-reviewed human form. Gastric protection data in humans is slightly stronger — BPC-157 was originally investigated as a gut-protective compound — but published human trial results remain unavailable.
Starting dose range (community practice, not clinical guidance): 250–500 mcg daily, subcutaneous or intramuscular proximal to the injury site. Oral or sublingual for gut applications.
What you’ll know after 8 weeks: Whether the specific injury or symptom you’re tracking improved, and at what rate. Whether you experienced adverse effects. You will not know whether BPC-157 caused the improvement or whether time and training modification did. That’s the honest epistemics of a single-person protocol.
A first-person field report on BPC-157 in rotator cuff recovery — including what was tracked and how — is in our BPC-157 rotator cuff field report.
Ipamorelin for GH Pulse Optimization
Mechanism: Ipamorelin is a selective growth hormone secretagogue — a synthetic peptide that binds to the ghrelin receptor and stimulates pulsatile GH release from the pituitary. Distinguished from earlier secretagogues like GHRP-6 by a more selective stimulation profile, with animal model data suggesting lower cortisol and prolactin co-stimulation (Ankersen et al., Journal of Medicinal Chemistry, 1998).
Starting dose range: 100–200 mcg per injection, once or twice daily. Timed to natural GH release windows — before sleep or post-exercise — based on receptor dynamics logic rather than published human dosing trials.
What a first protocol can tell you: IGF-1 before and after is a direct biomarker. It’s the most cleanly measurable output a beginner can track without sophisticated equipment. Test at baseline. Test at 8 weeks. That’s your data.
TB-500 for Systemic Recovery
Mechanism: TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cellular repair. In rodent models, effects on angiogenesis, inflammation modulation, and wound healing have been reported. A 2010 review (Goldstein et al., Annals of the New York Academy of Sciences) covered Thymosin Beta-4’s role across cardiac, skin, and corneal repair in animal models.
Use case for beginners: When systemic recovery — rather than site-specific repair — is the goal. Run it alone for a first cycle. The BPC-157 + TB-500 stack is widely discussed, but stacking removes your ability to attribute outcomes to either compound.
Protocol Structure: First 8 Weeks
| Week | Action |
|---|---|
| Week 0 (before) | Baseline labs: CMP, fasting IGF-1, fasting glucose. Write down your outcome metric and stopping criteria. |
| Weeks 1–8 | Daily injections at consistent time. Log anything notable. Midpoint check on outcome metric at week 4. |
| Week 8 (end) | Repeat labs. Compare to baseline. Evaluate outcome metric. Write your conclusions before you read anyone else’s. |
Injection Technique
Subcutaneous injection into the abdomen or thigh for most research peptides. Insulin syringes, 28–31 gauge, 0.5 inch. Reconstitution with bacteriostatic water. Standard dilution math: if you add 2ml BAC water to a 5mg vial, you have 2,500 mcg/ml — each 0.1ml unit on a U100 syringe delivers 250 mcg. Sterile technique is not optional.
What Beginners Consistently Get Wrong
Stacking too early. If you run three compounds simultaneously and feel better — or worse — you know nothing. You’ve created a confounded variable set with no control. Start with one compound.
Skipping baseline labs. You cannot evaluate a before-and-after without a before. Get bloodwork before the first injection. No exceptions.
Sourcing without verifying. Peptide purity in the gray market varies significantly. A 2017 analysis in Drug Testing and Analysis (Brennan et al.) tested 44 research peptides from online vendors and found 19 did not match label claims for concentration. Third-party mass spectrometry is the only real check on what’s in the vial.
FAQ — Beginner Peptide Protocol
What is a beginner peptide protocol?
One compound, one measurable outcome, baseline labs before you start, and a stopping criterion written down in advance. Not a stack. Not an optimization protocol. A single-variable experiment you can actually interpret.
Which peptides are best for beginners?
The three most frequently discussed starting points: BPC-157 for injury and gut applications, ipamorelin for GH pulse optimization (with IGF-1 as a clean biomarker), and TB-500 for systemic recovery. The evidence base for each is preclinical-dominant. None has robust human RCT data.
How long should a beginner peptide cycle be?
Eight weeks. Long enough to see a response if one is coming. Short enough that if something goes wrong you haven’t committed to months of exposure.
What labs should I get before starting?
Minimum: comprehensive metabolic panel and fasting IGF-1. Add fasting glucose and insulin if running a GH secretagogue. Add hormonal panel (total testosterone, free testosterone, LH, FSH) if running in any hormonal optimization context.
What dosing should beginners start with?
BPC-157: 250–500 mcg daily is community convention, drawn from animal model data not clinical trials. Ipamorelin: 100–200 mcg once or twice daily at GH release windows. These are not clinical recommendations. Start at the lower end of the range.
The first protocol you run teaches you one specific thing: how your body responds to one compound, under controlled conditions, in a defined window. That’s the asset. Not the compound — the data you generate by running it carefully. Do less. Measure more.